Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Amgen Reports Second Quarter 2016 Financial Results

      Amgen Logo.

      News provided by

      Amgen

      Jul 27, 2016, 04:01 ET

      Share this article

      Share this article


      THOUSAND OAKS, Calif., July 27, 2016 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the second quarter of 2016. Key results include:

      • Revenues increased 6 percent versus the second quarter of 2015 to $5.7 billion.
        • Product sales grew 5 percent driven by Enbrel® (etanercept), Prolia® (denosumab), KYPROLIS® (carfilzomib) and XGEVA® (denosumab).
      • GAAP earnings per share (EPS) increased 15 percent to $2.47 driven by higher revenues and higher operating margins.
        • GAAP operating income increased 15 percent to $2,380 million and GAAP operating margin improved by 3.8 percentage points to 43.5 percent.
      • Non-GAAP EPS increased 11 percent to $2.84 driven by higher revenues and higher operating margins.
        • Non-GAAP operating income increased 10 percent to $2,812 million and non-GAAP operating margin improved by 2.6 percentage points to 51.4 percent.
      • 2016 total revenues guidance increased to $22.5-$22.8 billion; EPS guidance increased to $9.55-$9.90 on a GAAP basis and $11.10-$11.40 on a non-GAAP basis.
      • The Company generated $2.5 billion of free cash flow.

      "We delivered another strong quarter and are on track to meet or exceed our long-term objectives," said Robert A. Bradway, chairman and chief executive officer. "We are in the early stages of a new product launch cycle and have several additional pipeline opportunities rapidly nearing regulatory milestones."


      $Millions, except EPS and percentages


      Q2'16


      Q2'15


      YOY Δ








      Total Revenues


      $ 5,688


      $ 5,370


      6%

      GAAP Operating Income


      $ 2,380


      $ 2,076


      15%

      GAAP Net Income


      $ 1,870


      $ 1,653


      13%

      GAAP EPS


      $   2.47


      $   2.15


      15%

      Non-GAAP Operating Income


      $ 2,812


      $ 2,551


      10%

      Non-GAAP Net Income


      $ 2,146


      $ 1,977


      9%

      Non-GAAP EPS


      $   2.84


      $   2.57


      11%


      References in this release to "non-GAAP" measures, measures presented "on a non-GAAP basis" and to "free cash flow" (computed by subtracting capital expenditures from operating cash flow) refer to non-GAAP financial measures. Adjustments to the most directly comparable GAAP financial measures and other items are presented on the attached reconciliations.

      Product Sales Performance

      • Total product sales increased 5 percent for the second quarter of 2016 versus the second quarter of 2015. The increase was driven by ENBREL, Prolia, KYPROLIS and XGEVA.
      • ENBREL sales increased 10 percent driven by net selling price, offset partially by the impact of competition.
      • Neulasta® (pegfilgrastim) sales decreased 1 percent driven by lower unit demand, offset partially by net selling price in the United States (U.S.).
      • Aranesp® (darbepoetin alfa) sales increased 5 percent. Unit demand grew due to a shift by some U.S. dialysis customers from EPOGEN® (epoetin alfa) to Aranesp. Unit demand growth was offset partially by unfavorable changes in inventory and net selling price.
      • Prolia sales increased 30 percent driven by higher unit demand.
      • Sensipar/Mimpara® (cinacalcet) sales increased 13 percent driven by net selling price and higher unit demand.
      • XGEVA sales increased 15 percent driven mainly by higher unit demand and, to a lesser extent, net selling price.
      • EPOGEN sales decreased 33 percent driven by the impact of competition and, to a lesser extent, a shift by some U.S. dialysis customers to Aranesp.
      • NEUPOGEN® (filgrastim) sales decreased 23 percent driven by the impact of competition in the U.S.
      • KYPROLIS sales increased 45 percent driven by higher unit demand.
      • Vectibix® (panitumumab) sales were flat.
      • Nplate® (romiplostim) sales increased 14 percent driven by higher unit demand.
      • BLINCYTO® (blinatumomab) sales increased 76 percent driven by higher unit demand.

      Product Sales Detail by Product and Geographic Region










      $Millions, except percentages


      Q2'16


      Q2'15


      YOY Δ



      US

      ROW

      TOTAL


      TOTAL


      TOTAL










      Enbrel®


      $1,423

      $61

      $1,484


      $1,348


      10%

      Neulasta®


      962

      187

      1,149


      1,158


      (1%)

      Aranesp®


      260

      244

      504


      479


      5%

      Prolia®


      286

      155

      441


      340


      30%

      Sensipar® / Mimpara®


      303

      86

      389


      344


      13%

      XGEVA®


      275

      106

      381


      331


      15%

      EPOGEN®


      331

      0

      331


      491


      (33%)

      NEUPOGEN®


      141

      55

      196


      256


      (23%)

      KYPROLIS®


      142

      30

      172


      119


      45%

      Vectibix®


      52

      108

      160


      160


      0%

      Nplate®


      84

      58

      142


      125


      14%

      BLINCYTO®

      21

      9

      30


      17


      76%

      Repatha®

      20

      7

      27


      0


      *

      Other**


      17

      51

      68


      57


      19%










      Total product sales


      $4,317

      $1,157

      $5,474


      $5,225


      5%










      * Not meaningful









      ** Other includes MN Pharma, Bergamo, IMLYGIC®and Corlanor®


      Operating Expense, Operating Margin and Tax Rate Analysis

      On a GAAP basis:

      • Cost of Sales margin improved by 1.6 percentage points driven primarily by manufacturing efficiencies and higher net selling price. Research & Development (R&D) expenses decreased 7 percent driven primarily by transformation and process improvement efforts and lower spending required to support certain later-stage clinical programs. Selling, General & Administrative (SG&A) expenses increased 11 percent driven primarily by investments in new product launches. Total Operating Expenses were flat year-over-year, with all expense categories reflecting savings from our transformation and process improvement efforts.
      • Operating Margin improved by 3.8 percentage points to 43.5 percent.
      • Tax Rate decreased by 2.0 percentage points, reflecting discrete benefits associated with tax incentives and the adoption of Accounting Standards Update 2016-09, Improvements to Employee Share-Based Payment Accounting (ASU 2016-09), offset partially by unfavorable changes in the geographic mix of earnings.

      On a non-GAAP basis:

      • Cost of Sales margin improved by 1.6 percentage points driven primarily by manufacturing efficiencies and higher net selling price. R&D expenses decreased 4 percent driven primarily by transformation and process improvement efforts and lower spending required to support certain later-stage clinical programs. SG&A expenses increased 13 percent driven primarily by investments in new product launches. Total Operating Expenses increased 2 percent, with all expense categories reflecting savings from our transformation and process improvement efforts.
      • Operating Margin improved by 2.6 percentage points to 51.4 percent.
      • Tax Rate decreased by 1.4 percentage points, reflecting discrete benefits associated with tax incentives and the adoption of ASU 2016-09, offset partially by unfavorable changes in the geographic mix of earnings.


      $Millions, except percentages







      GAAP


      Non-GAAP




      Q2'16


      Q2'15


      YOY Δ


      Q2'16


      Q2'15


      YOY Δ















      Cost of Sales

      $1,050


      $1,089


      (4%)


      $738


      $789


      (6%)


      % of product sales

      19.2%


      20.8%


      (1.6) pts


      13.5%


      15.1%


      (1.6) pts

      Research & Development

      $900


      $964


      (7%)


      $878


      $918


      (4%)


      % of product sales

      16.4%


      18.4%


      (2.0) pts


      16.0%


      17.6%


      (1.6) pts

      Selling, General & Administrative

      $1,292


      $1,160


      11%


      $1,260


      $1,112


      13%


      % of product sales

      23.6%


      22.2%


      1.4 pts


      23.0%


      21.3%


      1.7 pts

      Other

      $66


      $81


      (19%)


      $0


      $0


      0%

      TOTAL Operating Expenses

      $3,308


      $3,294


      0%


      $2,876


      $2,819


      2%














      Operating Margin













      operating income as a % of product sales

      43.5%


      39.7%


      3.8 pts


      51.4%


      48.8%


      2.6 pts















      Tax Rate

      15.2%


      17.2%


      (2.0) pts


      18.6%


      20.0%


      (1.4) pts















      pts: percentage points




      Cash Flow and Balance Sheet

      • The Company generated $2.5 billion of free cash flow in the second quarter of 2016 versus $3.2 billion in the second quarter of 2015. The decrease was driven by the timing of tax payments and the termination of foreign exchange forward contracts in the second quarter of 2015.
      • The Company's third quarter 2016 dividend of $1.00 per share declared on July 22, 2016, will be paid on Sept. 8, 2016, to all stockholders of record as of Aug. 17, 2016.
      • During the second quarter, the Company repurchased 3.9 million shares of common stock at a total cost of $591 million. At the end of the second quarter, the Company had $3.6 billion remaining under its stock repurchase authorization. 


      $Billions, except shares


      Q2'16


      Q2'15


      YOY Δ










      Operating Cash Flow

      $2.7


      $3.3


      ($0.6)

      Capital Expenditures

      0.2


      0.1


      0.1

      Free Cash Flow

      2.5


      3.2


      (0.7)

      Dividends Paid

      0.8


      0.6


      0.2

      Share Repurchase

      0.6


      0.5


      0.1

      Avg. Diluted Shares (millions)

      756


      768


      (12)










      Cash and Investments

      35.0


      30.0


      5.0

      Debt Outstanding

      33.2


      32.0


      1.2

      Stockholders' Equity

      30.1


      27.5


      2.6










            Note: Numbers may not add due to rounding


      2016 Guidance

      For the full year 2016, the Company now expects:

      • Total revenues in the range of $22.5 billion to $22.8 billion.
        • Previously, the Company expected total revenues in the range of $22.2 billion to $22.6 billion.
      • On a GAAP basis, EPS in the range of $9.55 to $9.90 and a tax rate in the range of 16.5 percent to 17.5 percent.
        • Previously, the Company expected GAAP EPS in the range of $9.34 to $9.74. Tax rate guidance is unchanged.
      • On a non-GAAP basis, EPS in the range of $11.10 to $11.40 and a tax rate in the range of 19.0 percent to 20.0 percent.
        • Previously, the Company expected non-GAAP EPS in the range of $10.85 to $11.20. Tax rate guidance is unchanged.
      • Capital expenditures to be approximately $700 million.  

      Second Quarter Product and Pipeline Update

      Key development milestones:


      Clinical Program

      Indication

      Milestone

      Repatha® (evolocumab)

      Hyperlipidemia

      Phase 3 coronary imaging data expected H2 2016

      Phase 3 CV outcomes data expected Q1 2017*

      KYPROLIS

      Newly diagnosed multiple myeloma

      Phase 3 data expected H2 2016*

      BLINCYTO®

      Pediatric Ph- R/R
      B-cell precursor ALL

      FDA priority review

      Parsabiv™ (etelcalcetide)†

      Secondary hyperparathyroidism

      Global regulatory reviews

      XGEVA

      Prevention of SREs in multiple myeloma

      Phase 3 data expected H2 2016*

      Romosozumab

      Postmenopausal osteoporosis

      US regulatory review

      Global regulatory submissions

      Erenumab (AMG 334)

      Migraine Prophylaxis

      Phase 3 episodic migraine data expected H2 2016

      ABP 215

      (biosimilar bevacizumab)

      Oncology

      Global regulatory submissions

      ABP 501

      (biosimilar adalimumab)

      Inflammatory diseases

      Global regulatory reviews

      ABP 980

      (biosimilar trastuzumab)

      Breast Cancer

      Global regulatory submissions


      *Event driven study; †Trade name provisionally approved by FDA; CV = cardiovascular; ALL = acute lymphoblastic leukemia

      The Company provided the following updates on selected product and pipeline programs:

      Repatha 

      • In July, the U.S. Food and Drug Administration (FDA) approved the Repatha Pushtronex™ system (on-body infusor with prefilled cartridge) for monthly single-dose administration.
      • Data from a Phase 3 study evaluating the effects of Repatha on atherosclerotic disease as measured by intravascular ultrasound are expected in H2 2016.
      • Data from an event driven Phase 3 study evaluating the effects of Repatha on cardiovascular outcomes are expected in Q1 2017.

      KYPROLIS

      • In June, the European Commission approved an expanded indication for KYPROLIS, to be used in combination with dexamethasone alone, for adult patients with multiple myeloma who have received at least one prior therapy, based on the ENDEAVOR data.
      • Data from the event driven Phase 3 CLARION study of KYPROLIS versus bortezomib in newly diagnosed, transplant ineligible multiple myeloma patients is expected in H2 2016.

      BLINCYTO

      • In May, FDA accepted for priority review the supplemental Biologics License Application for BLINCYTO to include new data supporting the treatment of pediatric and adolescent patients with Philadelphia chromosome‑negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia.  The Prescription Drug User Fee Act target action date is Sept. 1, 2016.

      Romosozumab

      • In July, a Biologics License Application for romosozumab for the treatment of osteoporosis in postmenopausal women at increased risk for fracture was submitted to FDA.

      Erenumab

      • In June, a global Phase 2 study evaluating the efficacy and safety of erenumab in chronic migraine prevention met its primary endpoint.

      ABP 980

      • In July, the primary analysis was completed for a Phase 3 study evaluating the efficacy and safety of ABP 980 compared with trastuzumab in patients with human epidermal growth factor receptor 2-positive early breast cancer.

      Erenumab is developed in collaboration with Novartis
      Romosozumab is developed in collaboration with UCB globally, as well as Astellas in Japan

      Non-GAAP Financial Measures

      In this news release, management has presented its operating results for the second quarters of 2016 and 2015 in accordance with U.S. Generally Accepted Accounting Principles (GAAP) and on a non-GAAP basis. In addition, management has presented its full year 2016 EPS and tax rate guidance in accordance with GAAP and on a non-GAAP basis. These non-GAAP financial measures are computed by excluding certain items related to acquisitions, restructuring and certain other items from the related GAAP financial measures. Reconciliations for these non-GAAP financial measures to the most directly comparable GAAP financial measures are included in the news release. Management has also presented Free Cash Flow (FCF), which is a non-GAAP financial measure, for the second quarters of 2016 and 2015. FCF is computed by subtracting capital expenditures from operating cash flow, each as determined in accordance with GAAP.

      The Company believes that its presentation of non-GAAP financial measures provides useful supplementary information to and facilitates additional analysis by investors. The Company uses certain non-GAAP financial measures to enhance an investor's overall understanding of the financial performance and prospects for the future of the Company's  ongoing business activities by facilitating comparisons of results of ongoing  business operations among current, past and future periods.  The Company believes that FCF provides a further measure of the Company's liquidity.

      The Company uses the non-GAAP financial measures set forth in the news release in connection with its own budgeting and financial planning internally to evaluate the performance of the business, including to allocate resources and to evaluate results relative to incentive compensation targets. The non-GAAP financial measures are in addition to, not a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP.

      About Amgen

      Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

      Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential. 

      For more information, visit www.amgen.com and follow us on www.twitter.com/amgen.

      Forward-Looking Statements

      This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

      No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with our products after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to acquire other companies or products and to integrate the operations of companies we have acquired may not be successful. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all. We are increasingly dependent on information technology systems, infrastructure and data security. Our stock price is volatile and may be affected by a number of events. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock.

      CONTACT:  Amgen, Thousand Oaks
      Trish Hawkins, 805-447-5631 (media)
      Arvind Sood, 805-447-1060 (investors)

      Amgen Inc.

      Consolidated Statements of Income - GAAP

      (In millions, except per share data)

      (Unaudited)
















      Three months ended


      Six months ended





      June 30,


      June 30,





      2016


      2015


      2016


      2015

      Revenues:










      Product sales


      $  5,474


      $  5,225


      $  10,713


      $  10,099


      Other revenues


      214


      145


      502


      304



      Total revenues


      5,688


      5,370


      11,215


      10,403












      Operating expenses:










      Cost of sales


      1,050


      1,089


      2,068


      2,122


      Research and development


      900


      964


      1,772


      1,858


      Selling, general and administrative


      1,292


      1,160


      2,495


      2,186


      Other


      66


      81


      98


      139



      Total operating expenses


      3,308


      3,294


      6,433


      6,305












      Operating income


      2,380


      2,076


      4,782


      4,098












      Interest expense, net


      313


      277


      607


      529

      Interest and other income, net


      137


      198


      287


      304












      Income before income taxes


      2,204


      1,997


      4,462


      3,873












      Provision for income taxes


      334


      344


      692


      597












      Net income


      $  1,870


      $  1,653


      $    3,770


      $    3,276












      Earnings per share:










      Basic


      $    2.49


      $    2.18


      $      5.01


      $      4.30


      Diluted


      $    2.47


      $    2.15


      $      4.97


      $      4.26












      Weighted average shares used in calculation of earnings per share:








      Basic


      751


      760


      753


      761


      Diluted


      756


      768


      759


      769

      Amgen Inc.

      Consolidated Balance Sheets - GAAP

      (In millions)

      (Unaudited)








      June 30,


      December 31,



      2016


      2015

      Assets





      Current assets:






      Cash, cash equivalents and marketable securities


      $  35,034


      $           31,382


      Trade receivables, net


      3,078


      2,995


      Inventories


      2,671


      2,435


      Other current assets


      2,164


      1,703



      Total current assets


      42,947


      38,515

      Property, plant and equipment, net


      4,884


      4,907

      Intangible assets, net


      11,068


      11,641

      Goodwill


      14,799


      14,787

      Other assets


      1,773


      1,599

      Total assets


      $  75,471


      $           71,449






      Liabilities and Stockholders' Equity





      Current liabilities:






      Accounts payable and accrued liabilities


      $    5,536


      $             6,417


      Current portion of long-term debt


      5,294


      2,247



      Total current liabilities


      10,830


      8,664

      Long-term debt


      27,928


      29,182

      Long-term deferred tax liability


      2,598


      2,239

      Other noncurrent liabilities


      3,982


      3,281

      Stockholders' equity


      30,133


      28,083

      Total liabilities and stockholders' equity


      $  75,471


      $           71,449








      Shares outstanding


      749


      754

      Amgen Inc.

      GAAP to Non-GAAP Reconciliations

      (In millions)

      (Unaudited)


















      Three months ended


      Six months ended 


      June 30, 


      June 30, 


      2016


      2015


      2016


      2015









      GAAP cost of sales

      $  1,050


      $      1,089


      $  2,068


      $      2,122

      Adjustments to cost of sales:








      Acquisition-related expenses (a)

      (312)


      (285)


      (623)


      (569)

      Certain net charges pursuant to our restructuring initiative

      -


      (15)


      -


      (29)

      Total adjustments to cost of sales

      (312)


      (300)


      (623)


      (598)

      Non-GAAP cost of sales

      $    738


      $         789


      $  1,445


      $      1,524









      GAAP cost of sales as a percentage of product sales

      19.2%


      20.8%


      19.3%


      21.0%

      Acquisition-related expenses

      -5.7


      -5.4


      -5.8


      -5.6

      Certain net charges pursuant to our restructuring initiative

      0.0


      -0.3


      0.0


      -0.3

      Non-GAAP cost of sales as a percentage of product sales

      13.5%


      15.1%


      13.5%


      15.1%









      GAAP research and development expenses

      $    900


      $         964


      $  1,772


      $      1,858

      Adjustments to research and development expenses:








      Acquisition-related expenses (a)

      (19)


      (28)


      (38)


      (49)

      Certain net charges pursuant to our restructuring initiative

      (3)


      (18)


      2


      (35)

      Total adjustments to research and development expenses

      (22)


      (46)


      (36)


      (84)

      Non-GAAP research and development expenses

      $    878


      $         918


      $  1,736


      $      1,774









      GAAP research and development expenses as a percentage of product sales

      16.4%


      18.4%


      16.5%


      18.4%

      Acquisition-related expenses (a)

      -0.3


      -0.5


      -0.3


      -0.5

      Certain net charges pursuant to our restructuring initiative

      -0.1


      -0.3


      0.0


      -0.3

      Non-GAAP research and development expenses as a percentage of product sales

      16.0%


      17.6%


      16.2%


      17.6%









      GAAP selling, general and administrative expenses

      $  1,292


      $      1,160


      $  2,495


      $      2,186

      Adjustments to selling, general and administrative expenses:








      Acquisition-related expenses (b)

      (27)


      (28)


      (128)


      (57)

      Certain net charges pursuant to our restructuring initiative

      (5)


      (20)


      (4)


      (24)

      Total adjustments to selling, general and administrative expenses

      (32)


      (48)


      (132)


      (81)

      Non-GAAP selling, general and administrative expenses

      $  1,260


      $      1,112


      $  2,363


      $      2,105









      GAAP selling, general and administrative expenses as a percentage of product sales

      23.6%


      22.2%


      23.3%


      21.6%

      Acquisition-related expenses (a)

      -0.5


      -0.5


      -1.2


      -0.6

      Certain net charges pursuant to our restructuring initiative

      -0.1


      -0.4


      0.0


      -0.2

      Non-GAAP selling, general and administrative expenses as a percentage of product sales

      23.0%


      21.3%


      22.1%


      20.8%









      GAAP operating expenses

      $  3,308


      $      3,294


      $  6,433


      $      6,305

      Adjustments to operating expenses:








      Adjustments to cost of sales

      (312)


      (300)


      (623)


      (598)

      Adjustments to research and development expenses

      (22)


      (46)


      (36)


      (84)

      Adjustments to selling, general and administrative expenses

      (32)


      (48)


      (132)


      (81)

      Certain net charges pursuant to our restructuring initiative (c)

      (8)


      (10)


      (10)


      (67)

      Expense related to various legal proceedings

      (78)


      (71)


      (105)


      (71)

      Acquisition-related adjustments

      20


      -


      17


      (1)

      Total adjustments to operating expenses

      (432)


      (475)


      (889)


      (902)

      Non-GAAP operating expenses

      $  2,876


      $      2,819


      $  5,544


      $      5,403









      GAAP operating income

      $  2,380


      $      2,076


      $  4,782


      $      4,098

      Adjustments to operating expenses

      432


      475


      889


      902

      Non-GAAP operating income

      $  2,812


      $      2,551


      $  5,671


      $      5,000









      GAAP operating income as a percentage of product sales

      43.5%


      39.7%


      44.6%


      40.6%

      Adjustments to cost of sales

      5.7


      5.7


      5.8


      5.9

      Adjustments to research and development expenses

      0.4


      0.9


      0.4


      0.8

      Adjustments to selling, general and administrative expenses

      0.6


      0.9


      1.2


      0.8

      Certain net charges pursuant to our restructuring initiative (c)

      0.2


      0.2


      0.1


      0.7

      Expense related to various legal proceedings

      1.4


      1.4


      1.0


      0.7

      Acquisition-related adjustments

      -0.4


      0.0


      -0.2


      0.0

      Non-GAAP operating income as a percentage of product sales

      51.4%


      48.8%


      52.9%


      49.5%









      GAAP income before income taxes

      $  2,204


      $      1,997


      $  4,462


      $      3,873

      Adjustments to operating expenses

      432


      475


      889


      902

      Non-GAAP income before income taxes

      $  2,636


      $      2,472


      $  5,351


      $      4,775









      GAAP provision for income taxes

      $    334


      $         344


      $    692


      $         597

      Adjustments to provision for income taxes:








      Income tax effect of the above adjustments to operating expenses (d)

      146


      151


      285


      290

      Other income tax adjustments (e)

      10


      -


      25


      -

      Total adjustments to provision for income taxes

      156


      151


      310


      290

      Non-GAAP provision for income taxes

      $    490


      $         495


      $  1,002


      $         887









      GAAP tax rate as a percentage of income before taxes

      15.2%


      17.2%


      15.5%


      15.4%

      Adjustments to provision for income taxes:








      Income tax effect of the above adjustments to operating expenses (d)

      3.0


      2.8


      2.7


      3.2

      Other income tax adjustments (e)

      0.4


      0.0


      0.5


      0.0

      Total adjustments to provision for income taxes

      3.4


      2.8


      3.2


      3.2

      Non-GAAP tax rate as a percentage of income before taxes

      18.6%


      20.0%


      18.7%


      18.6%









      GAAP net income

      $  1,870


      $      1,653


      $  3,770


      $      3,276

      Adjustments to net income:








      Adjustments to income before income taxes, net of the income tax effect

      286


      324


      604


      612

      Other income tax adjustments (e)

      (10)


      -


      (25)


      -

      Total adjustments to net income

      276


      324


      579


      612

      Non-GAAP net income

      $  2,146


      $      1,977


      $  4,349


      $      3,888


      Amgen Inc.

      GAAP to Non-GAAP Reconciliations

      (In millions, except per share data)

      (Unaudited)

















      The following table presents the computations for GAAP and non-GAAP diluted EPS.










      Three months ended


      Three months ended


      June 30, 2016


      June 30, 2015


      GAAP


      Non-GAAP


      GAAP


      Non-GAAP









      Net income

      $  1,870


      $      2,146


      $  1,653


      $      1,977

      Weighted-average shares for diluted EPS

      756


      756


      768


      768

      Diluted EPS

      $   2.47


      $        2.84


      $   2.15


      $        2.57










      Six months ended


      Six months ended


      June 30, 2016


      June 30, 2015


      GAAP


      Non-GAAP


      GAAP


      Non-GAAP









      Net income

      $  3,770


      $      4,349


      $  3,276


      $      3,888

      Weighted-average shares for diluted EPS

      759


      759


      769


      769

      Diluted EPS

      $   4.97


      $        5.73


      $   4.26


      $        5.06



      (a)

      The adjustments related primarily to non-cash amortization of intangible assets acquired in business combinations.












      (b)

      For the three months ended June 20, 2016 as well as the three and six months ended June 30, 2015, the adjustments related primarily to non-cash amortization of intangible assets acquired in business combinations.  For the six months ended June 30, 2016, the adjustments related primarily to a $73-million charge resulting from the reacquisition of Prolia®, XGEVA®and Vectibix®license agreements in certain markets from Glaxo Group Limited, as well as non-cash amortization of intangible assets acquired in business combinations.












      (c)

      The adjustments related primarily to severance expenses.












      (d)

      The tax effect of the adjustments between our GAAP and non-GAAP results takes into account the tax treatment and related tax rate(s) that apply to each adjustment in the applicable tax jurisdiction(s). Generally, this results in a tax impact at the U.S. marginal tax rate for certain adjustments, including the majority of amortization of intangible assets, whereas the tax impact of other adjustments, including restructuring expense, depends on whether the amounts are deductible in the respective tax jurisdictions and the applicable tax rate(s) in those jurisdictions. Due to these factors, the effective tax rates for the adjustments to our GAAP income before income taxes, for the three and six months ended June 30, 2016, were 33.8% and 32.1%, respectively, compared with 31.8% and 32.2% for the corresponding periods of the prior year.












      (e)

      The adjustments related to certain prior period items excluded from non-GAAP earnings, primarily the impact related to the stock options from the adoption of ASU 2016-09.

      Amgen Inc.

      Reconciliations of Cash Flows

      (In millions)

      (Unaudited)











      Three months ended


      Six months ended



      June 30,


      June 30,



      2016


      2015


      2016


      2015


      Net cash provided by operating activities

      $              2,677


      $              3,284

      (a)

      $              4,592


      $              4,766

      (a)

      Net cash used in investing activities

      (657)


      (2,359)


      (5,047)


      (3,311)


      Net cash (used in) provided by financing activities

      (2,286)


      6


      (1,059)


      (1,391)


      (Decrease) increase in cash and cash equivalents

      (266)


      931


      (1,514)


      64


      Cash and cash equivalents at beginning of period

      2,896


      2,864


      4,144


      3,731


      Cash and cash equivalents at end of period

      $              2,630


      $              3,795


      $              2,630


      $              3,795





















      Three months ended


      Six months ended



      June 30,


      June 30,



      2016


      2015


      2016


      2015


      Net cash provided by operating activities

      $              2,677


      $              3,284

      (a)

      $              4,592


      $              4,766

      (a)

      Capital expenditures

      (188)


      (133)


      (344)


      (251)


      Free cash flow

      $              2,489


      $              3,151


      $              4,248


      $              4,515



      (a) Restated to include $470 million and $623 million for the three and six months ended June 30, 2015, respectively, which was previously included in Net cash (used in) provided by financing activities, as a result of the adoption of ASU 2016-09.











      Reconciliation of GAAP EPS Guidance to Non-GAAP

      EPS Guidance for the Year Ending December 31, 2016

      (Unaudited)













      GAAP diluted EPS guidance


      $   9.55

      -

      $   9.90








      Known adjustments to arrive at non-GAAP*:






      Acquisition-related expenses

      (a)


      1.35



      Restructuring charges


      0.09

      -

      0.14


      Legal proceeding charge



      0.09



      Tax adjustments


      (b)


      (0.03)
















      Non-GAAP diluted EPS guidance


      $ 11.10

      -

      $ 11.40








      *

      The known adjustments are presented net of their related tax impact which amount to approximately $0.71 to $0.73 per share, in the aggregate.








      (a)

      The adjustments relate primarily to non-cash amortization of intangible assets acquired in prior year business combinations.








      (b)

      The adjustments relate to certain prior period items excluded from non-GAAP earnings.










      Reconciliation of GAAP Tax Rate Guidance to Non-GAAP

      Tax Rate Guidance for the Year Ending December 31, 2016

      (Unaudited)









      2016





      GAAP tax rate guidance

      16.5%

      -

      17.5%





        Tax rate effect of known adjustments discussed above



      2.5%






      Non-GAAP tax rate guidance

      19.0%

      -

      20.0%


      Logo - http://photos.prnewswire.com/prnh/20081015/AMGENLOGO

      SOURCE Amgen

      Modal title

      Also from this source

      AMGEN ANNOUNCES POSITIVE PHASE 3 RESULTS FOR DAZODALIBEP IN SJÖGREN'S DISEASE

      AMGEN ANNOUNCES POSITIVE PHASE 3 RESULTS FOR DAZODALIBEP IN SJÖGREN'S DISEASE

      Amgen (NASDAQ: AMGN) today announced results from the Phase 3 OASIZ-301 study of dazodalibep, the only global Phase 3 trial to demonstrate clinically ...

      NEW DATA AT AHA 2026 DEMONSTRATES THE VALUE OF TREATMENT WITH REPATHA® EARLIER IN THE CARDIOVASCULAR RISK CONTINUUM

      NEW DATA AT AHA 2026 DEMONSTRATES THE VALUE OF TREATMENT WITH REPATHA® EARLIER IN THE CARDIOVASCULAR RISK CONTINUUM

      Amgen (NASDAQ: AMGN) today announced new data at the American Heart Association (AHA) Scientific Sessions 2026 that further strengthen the case for...

      More Releases From This Source

      Explore

      Health Care & Hospitals

      Health Care & Hospitals

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      Biotechnology

      Biotechnology

      Earnings

      Earnings

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.